Who Attends
The program is designed for all size pharma/biotech companies, academia and investors seeking to enable a patient’s immune system to eradicate cancer.
The Complete Immuno-Oncology Ecosystem
BIOPHARMA RESPONSIBLE FOR
Cancer Immunotherapy • Immuno-Oncology • R&D Innovation & Strategy • Clinical R&D • Business Development • Preclinical and Translational Research • Biomarkers and Companion Dx • Early Stage Collaborations • Clinical Operations • Strategic Partnerships • External R&D • Licensing & Commercial Strategy
SOLUTION PROVIDERS
Diagnostic Testing • Biomarkers and Companion Dx • Assay Development • Next Gen Sequencing • mRNA / DNA Nucleic Acid Processing • RNA Sequencing • Cell Analysis/Manufacturing Platforms • Liquid Biopsies • Cancer Genetics • Immune Monitoring • Imaging Services • Flow Cytometry • Data Analysis/Analytics • Laboratory Services • Artificial Intelligence • CROs/Clinical Trial Design
INVESTMENT COMMUNITY INCLUDING
Investment Firms • Banks/Financial Institutions • Venture Capital • Private Equity • Foundation Capital • Analysts
ACADEMIA & RESEARCH ORGANIZATIONS FOCUSING ON
Immuno-Oncology / Cancer Immunotherapy • Oncology • Immunology • Cancer Vaccines • Adoptive T-Cell Therapy • Preclinical & Clinical R&D